Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Center for Infectious Disease Research (CIDRZ), Lusaka, Zambia.
J Int AIDS Soc. 2020 Feb;23(2):e25431. doi: 10.1002/jia2.25431.
Accurate costing is key for programme planning and policy implementation. Since 2011, there have been major changes in eligibility criteria and treatment regimens with price reductions in ART drugs, programmatic changes resulting in clinical task-shifting and decentralization of ART delivery to peripheral health centres making existing evidence on ART care costs in Zambia out-of-date. As decision makers consider further changes in ART service delivery, it is important to understand the current drivers of costs for ART care. This study provides updates on costs of ART services for HIV-positive patients in Zambia.
We evaluated costs, assessed from the health systems perspective and expressed in 2016 USD, based on an activity-based costing framework using both top-down and bottom-up methods with an assessment of process and capacity. We collected primary site-level costs and resource utilization data from government documents, patient chart reviews and time-and-motion studies conducted in 10 purposively selected ART clinics.
The cost of providing ART varied considerably among the ten clinics. The average per-patient annual cost of ART service was $116.69 (range: $59.38 to $145.62) using a bottom-up method and $130.32 (range: $94.02 to $162.64) using a top-down method. ART drug costs were the main cost driver (67% to 7% of all costs) and are highly sensitive to the types of patient included in the analysis (long-term vs. all ART patients, including those recently initiated) and the data sources used (facility vs. patient level). Missing capacity costs made up 57% of the total difference between the top-down and bottom-up estimates. Variability in cost across the ten clinics was associated with operational characteristics.
Real-world costs of current routine ART services in Zambia are considerably lower than previously reported estimates and sensitive to operational factors and methods used. We recommend collection and monitoring of resource use and capacity data to periodically update cost estimates.
准确的成本核算对于规划项目和实施政策至关重要。自 2011 年以来,艾滋病治疗药物的价格降低,资格标准和治疗方案发生了重大变化,临床工作任务转移,艾滋病治疗服务向基层卫生中心转移等项目变化,使得赞比亚现有的艾滋病治疗费用相关证据已经过时。随着决策者考虑进一步改变艾滋病治疗服务的提供方式,了解艾滋病治疗费用的当前驱动因素非常重要。本研究提供了赞比亚艾滋病毒阳性患者接受艾滋病治疗服务成本的最新信息。
我们根据基于活动的成本核算框架,采用自上而下和自下而上的方法,结合对流程和能力的评估,从卫生系统的角度评估了成本,并以 2016 年美元表示。我们从政府文件、患者病历审查和在 10 个有针对性选择的艾滋病治疗诊所进行的时间和运动研究中收集了一级站点成本和资源利用数据。
十个诊所提供艾滋病治疗服务的成本差异很大。使用自下而上的方法,每个患者每年接受艾滋病治疗服务的平均费用为 116.69 美元(范围:59.38 美元至 145.62 美元),使用自上而下的方法为 130.32 美元(范围:94.02 美元至 162.64 美元)。艾滋病治疗药物成本是主要的成本驱动因素(占所有成本的 67%至 7%),并且高度敏感于纳入分析的患者类型(长期患者与所有接受艾滋病治疗的患者,包括最近开始治疗的患者)和使用的数据来源(机构层面与患者层面)。缺失的能力成本占自上而下和自下而上估算之间总差异的 57%。十个诊所之间的成本差异与运营特征有关。
赞比亚当前常规艾滋病治疗服务的实际成本明显低于之前的报告估计,并且对运营因素和使用的方法敏感。我们建议收集和监测资源利用和能力数据,以定期更新成本估计。